Plus Therapeutics (PSTV) Stock Price
Plus Therapeutics Price
Revenue at Plus Therapeutics has contracted by 2.2% per year over the past 19 years to 5.21 M USD. For Plus Therapeutics, the net margin of -429.4% is up versus -2,719.8% a few years ago. The consensus 12-month price target for Plus Therapeutics is 2.04 USD, about 0.5% above where the stock trades today. Of 10 analysts, 9 rate the stock a buy — an overall Buy consensus.
Plus Therapeutics stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Plus Therapeutics business model & stock analysis
Frequently asked questions about Plus Therapeutics
Analysts currently set an average price target of 6.02 USD for the Plus Therapeutics stock (median: 2.04 USD), implying +196.5 % versus the latest price. The consensus is based on 10 analyst ratings.
11 analysts currently rate the Plus Therapeutics stock: 10 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Plus Therapeutics to generate revenue of 6.30 M USD and earnings per share of -8.37 USD.
Converted at the current exchange rate, the Plus Therapeutics share trades at 1.82 EUR (2.03 USD).
The Plus Therapeutics share (PSTV) is listed on 3 stock exchanges, including: NASDAQ (PSTV), Frankfurt (XMPA.F), München (XMPA.MU).
The expected revenue of Plus Therapeutics is 6.30 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Plus Therapeutics is -26.05 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Plus Therapeutics is currently -0.24. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Plus Therapeutics stock.
The price-to-sales ratio (P/S) of Plus Therapeutics is currently 1.00. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Plus Therapeutics stock.
The Eulerpool Quality Score for Plus Therapeutics is 3/10.
The ISIN of Plus Therapeutics is US72941H5090. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Plus Therapeutics is A2PPX6. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Plus Therapeutics is PSTV. The ticker symbol is used to trade Plus Therapeutics shares on the stock exchange.
Plus Therapeutics stock
Plus Therapeutics Peer Group
Plus Therapeutics Ticker
All fundamentals and in-depth analysis of Plus Therapeutics
Our stock analysis for Plus Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Plus Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.